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N-glycosylation is not essential for enzyme activity of
11-hydroxysteroid dehydrogenase type 2
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Division of Nephrology, University of Arkansas for Medical Sciences, and The John L. McClellan Veterans Affairs Hospital, Little Rock
Arkansas, USA
N-glycosylation is not essential for enzyme activity of 11-hydroxy-
steroid dehydrogenase type 2. 11 f3-hydroxysteroid dehydrogenase (1113-
HSD) catalyzes the oxidation of cortisol and corticosterone to cortisone
and il-dehydrocorticosterone, respectively. NAD-dependent I 1f3-HSD is
expressed at high levels in the distal nephron and contributes to miner-
alocorticoid specificity in that region. The present studies determined
whether N-glycosylation is necessary for the activity of NAD-dependent
I 1j3-HSD (1 1f3-HSD2). First, cultured human colonic epithelial cells (T84
cells), which express native 1113-HSD2 activity, were grown in medium
with and without tunicamycin, an inhibitor of N-glycosylation. Tunicamy-
cm had no effect on the enzyme activity. Next, the only putative N-
glycosylation site (Asn394-Leu395-Ser396) of the cloned human kidney
enzyme was eliminated by site-directed mutagenesis. Chinese hamster
ovary (CHO) cells transfected with either the wild-type or the mutant
eDNA construct showed no difference in the expressed enzyme activity,
and Western blot analysis showed that the 11 p-HSD2 protein was the
same size in cells expressing either the wild-type or the N394D mutant.
Likewise, the molecular mass of the 1113-HSD2 protein in T54 cells was not
altered by treatment with peptide-N-glycosidase F or tunicamycin. We
conclude that human I1p-HSD2 is not a N-glycoprotcin and N-glycosyl-
ation is not essential for the expression of enzyme activity.
11f3-hydroxysteroid dehydrogenase (EC 1.1.1.146) is a member
of the short-chain dehydrogenases/reductases (SDR) family [1]
and converts active glucocorticoids, such as cortisol and cortico-
sterone, to their inactive il-oxo metabolites. This metabolic
inactivation is believed to be an important mechanism whereby
tissues regulate the access of glucocorticoids to both glucocorti-
coid receptors and mineralocorticoid receptors. In mineralocorti-
coid responsive tissues, in particular, llp-HSD is critical in
preventing illicit occupancy and activation of mineralocorticoid
receptors by glucocorticoids [21.
Presently, two forms of 1 1f3-HSD have been identified: Type I
(1113-HSD1) utilizes NADP as co-factor, has low substrate
affinity and is active in both the oxidative and reductive directions
[31; Type 2 (11J3-HSD2) utilizes NAD as co-factor, has a high
affinity for its substrate and acts exclusively in the dehydrogenase
direction [4, 5]. 11p-HSD1 was purified originally from rat liver
[3], and the corresponding eDNA has been isolated [6]. The
I 1j3-EISD2 cDNA has also been cloned from a number of species,
including human [7—11]. 11p-HSD1 and 11f3-HSD2 share only
14% sequence-identity. Both human enzymes have potential
N-glycosylation sites (asparagine-X-serine/threonine) predicted
from their eDNA sequence: two in 1113-HSD1 and one in 1113-
HSD2.
A growing body of evidence indicates that 11J3-HSD2 is the
isoform responsible for modulating glucocorticoid activity in
mineralocorticoid target tissues. This isoform has been identified
in mineralocorticoid target cells in kidney [4, 9, 12, 131 and colon
[5, 13, 14]. However, the main support for the role of 1113-HSD2
in regulating glucocorticoid access to mineralocorticoid receptors
comes from studies of patients with "Apparent Mineralocorticoid
Excess" (AME), an inherited form of human hypertension result-
ing from a deficiency in 11 /3-HSD. Analysis of the 11 J3-HSD1 gene
from AME patients has shown no changes accountable for the
syndrome [151. On the other hand a number of inactivating
mutations in the 11/3-HSD2 gene have been demonstrated in
patients with the disorder [16—18].
Studies on I 1/3-HSD1 isoform have shown that it is an N-
glycoprotein and that N-glycosylation is important for full expres-
sion of the enzyme activity [19]. Putative N-glycosylation sites are
present in all of the cloned NAD-dependent 11/3-HSD except the
mouse enzyme [7—111. The rabbit NAD-dependent 11p-HSD was
recently reported not to be glycosylated [20]. However, there is no
information available concerning the role of glycosylation, if any,
on the activity of the human type 2 enzyme. This issue is pertinent
given the clear role of the human 11 3-HSD2 in regulating external
salt balance [15—19] and since the rabbit and human isoforms
possess different sites for N-glycosylation [7, 11]. The present
study was designed to address directly the role of N-glycosylation
in the enzyme activity of the human 11f3-HSD2 isoform.
METHODS
Cell culture
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T84 and CHO cells were obtained from American Type Culture
Collection. T54 cells were cultured in a 1:1 mixture of Dulbecco's
modified Eagle's medium (DMEM):F-12 nutrient mixture supple-
mented with 5% fetal calf serum. CHO cells were grown in Ham's
F-12 medium supplemented with 10% fetal calf serum. Cells were
grown in 6-well tissue culture dishes at 37°C under 5% CO2.
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Mutagenesis and transfection
The full-length sequence of the human I lp-HSD2 eDNA in the
pGEM4Z plasmid was kindly provided by Dr. Z. Krozowski [7].
The llp-HSD2 insert was excised with HindilI and XbaI and
ligated into the same restrictions sites of the pcDNA3 expression
plasmid (Invitrogen, San Diego, CA, USA). Site-directed mu-
tagenesis was performed in this plasmid using the Transformer
Site-Directed Mutagenesis Kit (Clontech Laboratories, Palo Alto,
CA, USA). The sequence of the mutants was verified by auto-
mated fluorescent sequencing (Prism DyeDeoxy Terminator se-
quencing kit; Perkin Elmer, Foster City, CA, USA) using an AB1
Model 373 sequencer.
CHO cells were transiently transfected with the wild-type and
mutant plasmids by lipofectin-mediated transfection. CHO cells
were grown to 60 to 80% confluence and washed twice with F-12
medium to remove any serum. The cells were then incubated for
18 hours with I ml F12 medium containing 10 tg Lipofectin
(Gibco BRL, Gaithersburg, MD, USA) and 0.5 g of wild-type or
mutant plasmid per well. The transfection mixture also contained
0.5 tg of the pSV-Gal plasmid (Promega, Madison, WI, USA) to
control for variations in the efficiency of transfection. At the end
of the transfection, the transfection mixture was aspirated and
replaced by standard culture medium and the cells were grown for
an additional 48 hours.
Dehydrogenase activity
Dehydrogenase activity was determined as described previously
[51. Briefly, cell monolayers were washed twice with PBS and then
incubated for either 30 minutes (T84 cells) or 120 minutes (CHO
cells) with serum-free culture medium containing 10 flM [3H]cor-
ticosterone. After completion of the incubation the culture me-
dium was removed, extracted with 2 volumes of ethyl acetate and
dried under N2. The dried extracts were dissolved in methanol
containing 5 msi of nonradioactive corticosterone and il-dehy-
drocorticosterone and applied to a TLC plate (TLC aluminium
sheets silica gel 60/kieselguhr F254, Merck). The plates were
developed with chloroform:methanol (95:5, vol/vol), the spots of
interest were localized under UV-light, cut from the plate and the
radioactivity measured by liquid scintillation spectroscopy.
3-galactosidase activity
Following the incubation with [3H]-corticosterone, the cell
monolayers were washed twice with PBS and then solubilized in
400 d of lysis buffer (100 m potassium phosphate, pH 7.8, 0.2%
Triton X-100). The galactosidase activity in the lysate was deter-
mined using a chemiluminescent reaction (Galacto-light; Tropix
Inc., Bedford, MA, USA) according to the manufacturer's proto-
col.
Enzymatic deglycosylation
Deglycosylation with Peptidc-N-glycosidase F (Boehringer
Manheim, Indianapolis, IN, USA) followed the manufacturer's
instructions. Briefly, 10 /.d (40 tg) microsomal protein from T84
cells, 18 d 60 m sodium phosphate buffer, pH 7.5, containing
150 mM EDTA and 0.2% sodium azide, 10 1d 10% SDS, and 2
2-mercaptoethanol were combined in a microfuge tube. The
samples were boiled for two minutes and then 10 rl 10% octyl
glucoside, 5 jd PNGase-F (200 U/mi) and 5 jii distilled water were
added. Reaction mixtures were incubated for 16 hours at 37°C, A
negative control contained all of the constituents except the
PNGase F. The deglycosylation efficiency was monitored in a
parallel reaction under the same conditions using 15 jtg car-
boxypeptidase-y as a PNGase-F substrate with and without en-
zyme. After completion of the incubation all samples were
separated on 10% SDS polyactylamide gel and transferred to
nitrocellulose membrane. The deglycosylation efficiency was ver-
ified by staining the lanes containing the carboxypeptidase sam-
ples with Ponceau S. T8 samples were processed for immunode-
tection.
Western blot analysis
Portions of the cell lysate (see above) containing 35 g protein
were separated by 10% SDS polyacrylamide gel electrophoresis
and transferred to a nitrocellulose membrane (Schleicher &
Schueli, Keene, NH, USA). Immunodetection was performed as
described previously using a polyclonal antibody against a human
11-HSD2 fusion protein [12]. Labeled bands were detected by
enhanced chemiluminescence (ECL, Amersham, Buckingham-
shire, UK).
RESULTS
A recent study demonstrated that at least partial N-glycosyla-
tion is required for expression of full activity of 11f3-HSDI [19].
To establish the importance of N-glycosylation for human 1113-
HSD2 activity, we grew T84 cells in presence or absence of
tunicamycin. T84 cells are derived from a human colon adenocar-
cinoma and express NAD-dependent 11/3-HSD2 enzyme activity
[5]. Tunicamycin blocks the first step of the assembly of the so
called "major lipid-oligosaccharide", an essential precursor in
N-glycosylation, thereby preventing N-glycosylation [21]. Figure 1
shows the effect of tunicamycin on I 1/3-HSD2 activity in T84 cells.
The cells grown in the presence of 100 ng/ml tunicamycin
exhibited a lower growth rate than in the control medium and
about a 20% reduction in total enzyme activity in comparison with
the control cells (not shown). However, the specific activity of
I1p-HSD in tunicamycin-treated cells, relative to the protein
content of the well, was virtually identical to that of the control
cells.
To address more directly a possible role for N-glycosylation in
the expression and function of 11f3-HSD2, we performed site-
directed mutagenesis. First, Asn394 was converted to Asp, thereby
eliminating the only predicted N-glycosylation site of the human
1113-HSD2. CHO cells were transfected with plasmid encoding
either the N594D mutant or the wild type enzyme. The cells again
were grown in absence or presence of tunicamycin (100 ng/ml
medium) and the expressed I 1p-HSD2 activity was measured.
The transfection efficiency was monitored by co-transfection with
13-galactosidase, and only wells with similar 13-galactosidase activ-
ity (± 10%) were used for determination of 11/3-HSD2 activity.
The results are presented in Figure 2. Nontransfected CHO cells
had virtually no enzyme activity. However, transfection of CHO
cells with either the wild-type or the N594D l1/3-HSD2 mutant
produced a significant expression of enzyme activity. Cells grown
in the presence of tunicamycin exhibited about a 25% decrease in
the activty in both wild-type and mutant enzymes. That is, either
in the presence or absence of tunicamycin, the N594D mutant,
yielded identical enzyme activity as the wild-type.
Western blot analysis of the 11p-HSD2 protein from CHO cells
transfected with wild-type enzyme and N394D mutant is presented
.'i- a-PU --
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Tunicamycin, ng/mI
Fig. 1. 11j3-hydroxysteroid dehydrogenase activity of T84 cells grown in
the presence or absence of 100 ag/mI tunicamycin. Tunicamycin-treated
cells were grown for four days in the presence of this agent prior to the
assay of enzyme activity. The enzyme activity is expressed as the amount
of il-dehydrocorticosterone formed during a 30 minute incubation rela-
tive to the protein content of the culture dish. N = 3 for each column.
Tunicamycin, ng/mI
Fig. 2. 11-hydroxysteroid dehydrogenase activity of CHO cells trans.
fected with either wild type or N394D mutant 11-HSD2. The left three
columns represent cells grown in the absence of tunicamycin. The right
three columns represent cells grown in the presence of 100 nglml
tunicamycin. Enzyme activity was determined as described in the Methods
section, and is expressed as the percentage conversion of corticosterone to
il-dehydrocorticosterone by a 35 mm dish of cells during a 120 minute
incubation. N = 3 for each column. Symbols are: (•) non-transfected; ()
wild-type; (LI) N394D.
1 2 3
Fig. 3. Western blot analysis of llfi.HSD2 protein in non.transfected
CHO cells (lane 1) or CHO cells expressing either the wild type
113-HSD2 (lane 2) or the N394D 11.3-HSD2 (lane 3). Molecular weight
markers are shown on the right. The antibody, against the C-terminal
portion of the human I 1/3-HSD2 protein, did not detect any 1113-HSD2 in
the non-transfected cells. Both the wild-type and N394D transfected cells
yielded bands of the same size and intensity.
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in Figure 3. As expected, no bands corresponding to 11f3-HSD2
were detected in non-transfected cells (lane 1). In cells transfected
with wild-type (lane 2) and N394D (lane 3) plasmids, the 1113-
FISD2 antibody recognized protein bands of the appropriate size
for 1113-HSD2. Of note, the 11/3-HSD2 bands in lanes 2 and 3 are
the same size, about 42 kDa in both cases, suggesting that the
wild-type enzyme is not an N-glycoprotein. As noted by others [12,
221, the 11/3-HSD2 protein migrates at a slightly faster rate than
expected from its predicted molecular mass (44 kDa).
To confirm the finding that the human 1113-HSD2 is not an
N-glycoprotein and to exclude the possibility that CHO cells
simply did not glycosylate the heterologously expressed protein,
microsomal proteins from T84 cells were treated with peptide-N-
glycosidase F. Figure 4 presents a Western blot of T84 microsomal
proteins not treated (lane I) and treated (lane 2) with PNGase F.
Clearly, treatment with PNGase F, a peptide glycosidase which
cleaves the bond between asparagine and the first (reducing)
N-acetylglucosamine of the oligosaccharide chain(s) of N-glyco-
proteins, produced no change in the molecular mass of the
recognized protein bands. In the control reaction under the same
conditions full deglycosylation of carboxypeptidase y (an N-
glycoprotein) was achieved (results not shown). These results
(Fig. 4) provide further proof that human 1113-HSD2 is not an
N-glycoprotein.
DISCUSSION
N-glycosylation is one of the most common post-translational
modifications of proteins in eukaryotic cells. Occurring in the
endoplasmic reticulum, N-glycosylation is essential for the expres-
sion of biological function in a variety of proteins. For most
members of the SDR family, however, enzyme activity does not
seem to depend on N-glycosylation. One exception is II 13-HSD
type 1, which requires at least partial N-glycosylation for normal
activity [19]. The 11/3-HSD type 2 is the most recently cloned
member of the SDR family and is an important determinant of
mineralocorticoid actions in target epithelia [7, 10]. The present
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C-terminus of I ip-HSD2 in the human (N394) and rat enzyme
(N392), such sites are absent in 1113-HSD2 from sheep or rabbit
[7—11]. Likewise, the only putative sites for N-glycosylation in the
rabbit enzyme (N272) and the sheep enzyme (N245) are absent in
the human and rat. Finally, the mouse enzyme lacks any sites for
N-glycosylation [81. Since the enzymatic characteristics of 1113-
HSD2 from these species are quite similar [4, 5, 8, 10, 141, it might
be anticipated that N-glycosylation is not essential for I 1/3-HSD2
function. The present results indicate that, indeed, this is the case.
The lack of a role for N-glycosylation of 11p-HSD2, in contrast to
the Type 1 enzyme [19], is yet another feature which differentiates
between these two isoforms of 11/3-hydroxysteroid dehydroge-
nase.
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Fig. 4. Western blot analysis of T84 cell microsomal proteins which were
either not treated (lane 1) or treated (lane 2) with peptide.N-glycosidase
F. In both cases the antibody recognized a protein band with exactly the
same molecular mass.
study examined whether N-glycosylation has any effect on the
activity of the human 11 /3-HSD2 isoform.
The results of the present study provide several lines of
evidence showing that N-glycosylation is not essential for human
I l/3-HSD2 activity. First, tunicamycin an inhibitor of N-glycosyl-
ation did not affect the activity of the native enzyme in cultured
T84 cells (Fig. 1). Second, elimination of the only predicted site for
N-glycosylation in the 11/3-HSD2 by site-directed mutagenesis
(mutation N394D) had no effect on the enzyme activity (Fig. 2).
Both sets of results support the conclusion that N-glycosylation is
not essential for full expression of I lp-HSD2 activity. Third,
Western blot analyses of the wild-type enzyme and the N394D
mutant expressed in CHO cells (Fig. 3), microsomal proteins from
T84 cells grown with and without tunicamycin (data not shown),
and microsomal proteins from T-84 cells treated with PNGase F
(Fig. 4) did not demonstrate any difference in the size of the
recognized proteins. In all cases the protein bands had the same
electrophoretic mobility and were localized in the area of 42 kDa.
These data are consistent with the view that the native human
I 113-HSD2 possesses no N-linked oligosaccharide chain.
The results of the present study demonstrated in independent
ways that human 1113-HSD2 is not an N-glycoprotein. Likewise,
Naray-Fejes-Toth and Fejes-Toth [20] found that the rabbit
11f3-HSD2 enzyme, which contains a different predicted N-
glycosylation site [11], was not glycosylated when expressed in
CHO cells. The lack of a role of N-glycosylation in I 1f3-HSD2
activity is also consistent with the observation that the sites for
N-glycosylation are not heavily conserved across species. For
example, while a site for N-glycosylation is present near the
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